Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aceclofenac + paracetamol (Sanjivani Parenteral)
- Development stage
- Unknown
- Lead developer
- Sanjivani Parenteral
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tydol is a fixed-dose combination tablet containing the non-steroidal anti-inflammatory drug (NSAID) aceclofenac (100 mg) and the analgesic/antipyretic paracetamol (325 mg). Developed and marketed by Sanjivani Parenteral, this oral combination is approved for the management of acute pain, inflammation, and fever associated with musculoskeletal disorders, osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Aceclofenac acts as a selective inhibitor of cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis to alleviate pain and swelling. Paracetamol acts centrally to inhibit prostaglandin synthesis in the central nervous system and modulate the brain's temperature-regulating center, providing complementary analgesic and antipyretic effects. Together, the two active ingredients provide synergistic, dual-action relief for moderate to severe pain.
- Brand names
- Tydol
- Other names
- aceclofenac + acetaminophenaceclofenac and paracetamolaceclofenac/paracetamol
02
Targets
COX-3 (Prostaglandin-endoperoxide synthase 1 splice variant)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on aceclofenac + paracetamol (Sanjivani Parenteral).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aceclofenac + paracetamol (Sanjivani Parenteral).